.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

VIMPAT Drug Profile

« Back to Dashboard
Vimpat is a drug marketed by Ucb Inc and is included in three NDAs. It is available from two suppliers. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has nineteen patent family members in eleven countries.

The generic ingredient in VIMPAT is lacosamide. There are twenty-one drug master file entries for this compound. Five suppliers are listed for this compound. There are five tentative approvals for this compound. Additional details are available on the lacosamide profile page.

Summary for Tradename: VIMPAT

Patents:1
Applicants:1
NDAs:3
Suppliers / Packagers: see list2
Drug Prices: :see details

Pharmacology for Tradename: VIMPAT

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc
VIMPAT
lacosamide
SOLUTION;ORAL022255-001Apr 20, 2010RXYes► subscribe► subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-001Oct 28, 2008RXNoRE38551► subscribeYY ► subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-004Oct 28, 2008RXYes► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VIMPAT

These historical archives are available as an add-on to one-year subscriptions.
See the Subscription Options for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-002Oct 28, 20085,654,301► subscribe
Ucb Inc
VIMPAT
lacosamide
SOLUTION;INTRAVENOUS022254-001Oct 28, 20085,654,301► subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-003Oct 28, 20085,654,301► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: VIMPAT

Drugname Dosage Strength RLD Submissiondate
lacosamide Injection10 mg/mL, 20 mLVimpat 6/30/2016
lacosamideOral Solution10 mg/mLVimpat10/29/2012
lacosamideTablets50 mg, 100 mg, 150 mg, and 200 mgVimpat10/29/2012

Non-Orange Book Patents for Tradename: VIMPAT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,773,475 Anticonvulsant enantiomeric amino acid derivatives► subscribe
6,048,899 Anticonvulsant enantiomeric amino acid derivatives► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIMPAT

Country Document Number Estimated Expiration
Spain2157567► subscribe
World Intellectual Property Organization (WIPO)9733861► subscribe
Japan3145414► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VIMPAT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00376Netherlands► subscribePRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE: EU/1/08/470/001-016 20080829
C0006France► subscribePRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/470/001 DU 20080829; REGISTRATION NO/DATE AT EEC: EU/1/08/470/001 DU 20080829
0888289/01Switzerland► subscribePRODUCT NAME: LACOSAMIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 59004 28.08.2009
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc